Cargando…

Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia

This study aimed to elucidate the mechanisms explaining the persistence of anemia and resistance to recombinant human erythropoietin (rHuEPO) therapy in a rat model of chronic kidney disease (CKD)-associated anemia with formation of anti-rHuEPO antibodies. The remnant kidney rat model of CKD induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garrido, Patrícia, Ribeiro, Sandra, Fernandes, João, Vala, Helena, Rocha-Pereira, Petronila, Bronze-da-Rocha, Elsa, Belo, Luís, Costa, Elísio, Santos-Silva, Alice, Reis, Flávio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730274/ https://www.ncbi.nlm.nih.gov/pubmed/26712750 http://dx.doi.org/10.3390/ijms17010028

Ejemplares similares

Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model
por: Garrido, Patrícia, et al.
Publicado: (2015)

Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis
por: do Sameiro-Faria, Maria, et al.
Publicado: (2014)

Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study
por: do Sameiro-Faria, Maria, et al.
Publicado: (2013)

Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese
por: Belo, Luís, et al.
Publicado: (2014)

Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
por: Coimbra, Susana, et al.
Publicado: (2021)

Bilirubin is independently associated with oxidized LDL levels in young obese patients
por: Nascimento, Henrique, et al.
Publicado: (2015)

Polymorphisms of the ELANE Gene Promoter Region in End-Stage Chronic Kidney Disease Patients
por: Fernandes, Rafael, et al.
Publicado: (2016)

Cardiovascular Risk Factors in Portuguese Obese Children and Adolescents: Impact of Small Reductions in Body Mass Index Imposed by Lifestyle Modifications
por: Nascimento, Henrique, et al.
Publicado: (2012)

The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index
por: Coimbra, Susana, et al.
Publicado: (2019)

Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers
por: Sereno, José, et al.
Publicado: (2014)

Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model
por: Sereno, José, et al.
Publicado: (2014)

Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia
por: Fernandes, J. C., et al.
Publicado: (2014)

Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients
por: Belo, Luís, et al.
Publicado: (2019)

Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality
por: Valente, Maria João, et al.
Publicado: (2019)

Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis
por: Rocha, Susana, et al.
Publicado: (2021)

Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis
por: Coimbra, Susana, et al.
Publicado: (2020)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease
por: Coimbra, Susana, et al.
Publicado: (2022)

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis
por: Coimbra, Susana, et al.
Publicado: (2023)

Neutrophil Elastase Inhibitors and Chronic Kidney Disease
por: Bronze-da-Rocha, Elsa, et al.
Publicado: (2018)

Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat
por: Teixeira, M., et al.
Publicado: (2012)

Inflammatory Disturbances in Preeclampsia: Relationship between Maternal and Umbilical Cord Blood
por: Catarino, Cristina, et al.
Publicado: (2012)

Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Trends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection
por: Sullivan, Patrick S, et al.
Publicado: (2011)

Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T) as a Risk Factor for Arterial Thrombosis in Georgian Patients
por: Garakanidze, Sopio, et al.
Publicado: (2018)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Science review: Recombinant human erythropoietin in critical illness: a role beyond anemia?
por: Coleman, Thomas, et al.
Publicado: (2004)

MicroRNAs Expression Profiles in Cardiovascular Diseases
por: Bronze-da-Rocha, Elsa
Publicado: (2014)

Impact of inflammation on anemia of hemodialysis patients who were under treatment of recombinant human erythropoietin
por: Rafiean-Kopaie, Mahmoud, et al.
Publicado: (2013)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

TNFR2 as a Potential Biomarker for Early Detection and Progression of CKD
por: Lousa, Irina, et al.
Publicado: (2023)

The Efficacy of Recombinant Human Erythropoietin in Treatment Chemotherapy Induced Anemia in Children Diagnosed with a Solid Cancer
por: Hiradfar, AA, et al.
Publicado: (2014)

Efficacy and safety of recombinant human erythropoietin (Hema-Plus(®)) for management of anemia in Thai patients on peritoneal dialysis
por: Chuengsaman, Piyatida, et al.
Publicado: (2021)

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
por: Debeljak, Nataša, et al.
Publicado: (2014)

Recombinant Human Erythropoietin Therapy for a Jehovah's Witness Child With Severe Anemia due to Hemolytic-Uremic Syndrome
por: Woo, Da Eun, et al.
Publicado: (2016)

Effects of Recombinant Erythropoietin on Hemoglobin Levels and Blood Transfusion Needs in Patients with Preoperative Anemia Undergoing Cardiac Surgery
por: Totonchi, Ziae, et al.
Publicado: (2022)

P1482: RECOMBINANT ERYTHROPOIETIN IN AUTOIMMUNE HEMOLYTIC ANEMIA WITH INADEQUATE RETICULOCYTOSIS: A SINGLE CENTER PROSPECTIVE STUDY
por: Luca Pedone, Giacinto, et al.
Publicado: (2023)

The Clinical Impact of Recombinant Human Erythropoietin
por: Muirhead, N
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_vd6c6od89ltqe8b4u46rp8murt